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hAda3 Degradation by Papillomavirus Type 16 E6 Correlates with
Abrogation of the p14ARF-p53 Pathway and Efficient
Immortalization of Human Mammary
Epithelial Cells
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Received 15 November 2007/Accepted 29 January 2008
Two activities of human papillomavirus type 16 E6 (HPV16 E6) are proposed to contribute to the efficient
immortalization of human epithelial cells: the degradation of p53 protein and the induction of telomerase.
However, the requirement for p53 inactivation has been debated. Another E6 target is the hAda3 protein, a p53
coactivator and a component of histone acetyltransferase complexes. We have previously described the role of
hAda3 and p53 acetylation in p14ARF-induced human mammary epithelial cell (MEC) senescence (P. Sekaric,
V. A. Shamanin, J. Luo, and E. J. Androphy, Oncogene 26:6261–6268, 2007). In this study, we analyzed a set
of HPV16 E6 mutants for the ability to induce hAda3 degradation. E6 mutants that degrade hAda3 but not p53
could abrogate p14ARF-induced growth arrest despite the presence of normal levels of p53 and efficiently
immortalized MECs. However, two E6 mutants that previously were reported to immortalize MECs with low
efficiency were found to be defective for both p53 and hAda3 degradation. We found that these immortal MECs
select for reduced p53 protein levels through a proteasome-dependent mechanism. The findings strongly imply
that the inactivation of the p14ARF-p53 pathway, either by the E6-mediated degradation of p53 or hAda3 or
by cellular adaptation, is required for MEC immortalization.
Human papillomavirus type 16 (HPV16) causes 50% of
the cervical cancer burden. Its E6 and E7 proteins exhibit
transforming properties through complex mechanisms. HPV16
E6 has been shown to induce p53 degradation and to stim-
ulate the expression of human telomerase reverse transcrip-
tase (hTERT). HPV16 E6 efficiently immortalizes primary
mammary epithelial cells (MECs), but the contributions of
p53 inactivation and hTERT activation remain controversial.
In general, the immortalization of human epithelial cells has
been associated with the activation of telomerase and the dis-
ruption of the p14ARF-p53 and p16-retinoblastoma pathways.
Some primary human cells can be immortalized by the forced
expression of hTERT alone, but these replicating cells select
for reduced p14ARF and/or p16ink4a expression (8, 28, 32).
The activation of p53 can induce cell senescence, transient
growth arrest, or apoptosis (reviewed in reference 13). p53
activation is manifested by the stabilization of the protein and
complex posttranslational modifications, including acetylation
and phosphorylation (reviewed in reference 3). Activated p53
regulates the transcription of several target genes, including
p21cip1, and also has transcription-independent functions in
apoptosis (reviewed in references 13 and 26). p53 acetylation is
found during replicative and oncogene-induced senescence or
stress-induced senescence. The major negative regulator of
p53 is MDM2 (Hdm2 in human cells), which can ubiquitinate
p53 and inhibit p53 acetylation (reviewed in reference 22).
ARF (p14 in human cells, p19 in mouse cells) is a tumor
suppressor that binds MDM2, inhibits MDM2 ubiquitin ligase
function, stabilizes p53 (reviewed in reference 33), and induces
p53 acetylation (20, 31).
Histone acetyltransferases (HATs) are essential components
of eukaryotic transcription complexes. Apart from acetylating
histones, several HATs (p300, CBP, PCAF, TIP60, and
hMOF) acetylate p53 and function as p53 coactivators (re-
viewed in references 3 and 36). ADA3 (for alteration/defi-
ciency in activation) is a component of yeast HAT complexes
and is required for nucleosomal histone acetylation (1). Hu-
man Ada3 (hAda3) is a transcriptional coactivator of p53 as
well as retinoic and estrogen receptors (15, 21, 37, 38). We
recently reported that the RNA interference-mediated knock-
down of hAda3 expression and truncated dominant-negative
hAda3 abrogated the acetylation of lysine 382 in p53, inhibited
p53 stabilization, and attenuated p14ARF-induced senescence
(31).
We previously reported that E6 mutations at amino acids
Phe 2 and Tyr 54 immortalized MECs but were incapable of
inducing p53 degradation. Importantly, E6Y54D-immortalized
MECs are resistant to p14ARF-induced senescence despite
normal levels of wild-type p53, which can be activated by DNA
damage (32). E6Y54D induces the degradation of hAda3 (31),
suggesting a mechanism for inhibiting p14ARF senescence
signaling to p53 that is distinct from p53 degradation. These
observations were consistent with the finding that the HPV16
E6 binding of hAda3 protein correlated with its ability to
immortalize MECs (15).
Here, we sought to critically evaluate the correlation be-
tween E6-induced Ada3 degradation and the inhibition of p53
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activation by p14ARF. We tested a series of p53 degradation-
defective HPV16 E6 mutants for hAda3 degradation and the
inhibition of p14ARF-p53 signaling. We demonstrate that
hAda3 degradation-competent E6 mutants block p14ARF-in-
duced p53 acetylation and growth arrest and immortalize
MECs. In contrast, E6 mutants defective for both p53 and
hAda3 degradation are much less potent in inhibiting
p14ARF-induced p53 activation. Notably, with this class of
mutants, cells become immortal after a crisis period and dis-
play reduced levels of p53 protein. All MECs immortalized by
E6 mutants express hTERT, implying that hAda3 degradation
is not required for hTERT induction. In summary, we describe
three subsets of p53 degradation-defective E6 mutants: those
able to induce Ada3 degradation efficiently immortalized
MECs; those unable to degrade Ada3 can lead to immortal
MECs that avoid senescence by degrading p53; and those that
do not degrade Ada3 and do not stimulate hTERT expression
fail to immortalize. Thus, we have used HPV E6 to discern the
requisite roles of hAda3 and cell adaptation in the inactivation
of the p14ARF-p53 pathway during epithelial cell immortal-
ization.
MATERIALS AND METHODS
Plasmids and cells. Plasmids, cells, and reagents and methods for cell culture,
Western blotting, reverse transcription-PCR (RT-PCR), and flow cytometry
were as described previously (31) unless otherwise noted. pcDNA3-p14ARF was
provided by C. Sherr. pEGFPF, encoding farnesylated enhanced green fluores-
cent protein (EGFP), was from W. Jiang. HPV16 E6 mutants in pLXSN were
described previously (18). The phenotypes of HPV16 E6 mutants are shown in
Table 1. pBabe-puro-11E6 was from L. Gustavo. pLXSN-6bE6 was provided by
M. Tommasino. The E6 sequence from the HPV6vc plasmid was amplified by
PCR and cloned into pLXSN, and the sequence was confirmed. HPV6vc E6
differs from HPV6b E6 by having a glutamine at position 50 instead of a histi-
dine.
Antibodies. The following antibodies were used: p14ARF (14P03; 1:100; Neo-
markers), p53 DO-1 (1:500; Santa Cruz), FL393 (1:500; Santa Cruz), p21cip1
(SX118; 1:200; Pharmingen), Flag (M2; 1:3,000; Sigma), HDM2 (clone IF2;
Ab-1; 1:400; Oncogene Research), actin (A2066; 1:4,000; Sigma), goat anti-
mouse horseradish peroxidase (1:4,000; Jackson), goat anti-rabbit horseradish
peroxidase (1:4,000; Jackson), and K382-acetylated p53 (2525; 1:1,000; Cell Sig-
naling).
Treatment with MG132. For studies with the proteasome inhibitor MG132,
106 cells were seeded in 100-mm dishes and grown for 24 h. MG132 in dimeth-
ylsulfoxide (DMSO) was added to a 10 M concentration, and the cells were
incubated for 4 h.
RT-PCR. HPV16 E6 RNA was detected by RT-PCR using primers 16E6S
(dAAGCAACAGTTACTGCGACGTGAG) and 16E6A (dCGGTCCACCGA
CCCCTTATATT). E6 mRNA of different HPV types was detected by RT-PCR
using the following primers to LXSN sequences flanking the E6 cloning site:
pLXSN1S (dTTTAACCGAGACCTCATCACC) and pLXSN1A (dCCACACC
CTAACTGACACACA).
RESULTS
HPV16 E6Y54D inhibits p14ARF-induced p53 acetylation.
MECs transduced by exogenous hTERT select for the down-
regulation of p14ARF expression during serial passage (32).
These cells are susceptible to p53-dependent senescence by
ectopic p14ARF. In contrast, E6Y54D-immortalized MECs
constitutively express p14ARF and undergo transient growth
arrest but not senescence in response to p14ARF (32). Since
E6Y54D does not degrade the p53 protein, the E6 inhibition of
p14ARF senescence signals and E6-mediated p53 degradation
are distinguishable.
Since E6Y54D degrades Ada3, we predicted it would inter-
fere with the p14ARF-induced stabilization and acetylation of
p53 in MECs. To test this, late-passage hTERT or E6Y54D-
immortalized MECs were infected with p14ARF-expressing
retroviruses. At day 7 postinfection, when hTERT MECs dis-
played the senescent phenotype (32), the levels of total p53
and lysine 382-acetylated p53 were analyzed. Ectopic p14ARF
induced the accumulation of total and K382-acetylated p53 in
hTERT MECs (Fig. 1A, lanes 1 and 2), but this response was
effectively blocked in E6Y54D MECs (lanes 5 and 6). To prove
that this was not a clonal effect specific for E6Y54D MECs,
late-passage hTERT MECs were infected with recombinant
E6Y54D-expressing retroviruses, and the selected population
was challenged with p14ARF. Consistently with the prior ex-
periments, E6Y54D inhibited p53 stabilization (Fig. 1, lanes 3
and 4). These data demonstrate that in MECs, HPV16 E6 can
inhibit p53 activation induced by p14ARF independently of
p53 degradation.
We sought to confirm the effects of E6 in another cell model.
U2OS osteosarcoma cells are p14ARF deficient and express
wild-type p53, so they are commonly used to study p53 and
p14ARF functions (34). In contrast to primary MECs or
hTERT MECs, U2OS cells are readily transfectable, and the
TABLE 1. Phenotype of HPV16 E6 mutants
HPV16 E6
protein
p53 degradation
in vivo
hADA3 degradation
in vivo
p53 levels in MECse Induction of
hTERT
Immortal
MECgEarly passage Late passage
Wild type   Lowa Lowa  6 (6)a
F2V   Normala Normala  3 (4)a
Y54D   Normalb Normalb  2 (2)
L37S   Normala Lowa  1 (2)a
L110Q   Normala Lowa  1 (2)a
G130V   Normalc NAf d 0 (2)c
L50G   Normalc NA d 0 (2)c
a Data are from reference 18.
b Data are from reference 32.
c Data are from Shamanin and Androphy, unpublished.
d Data are from reference 30.
e Normal indicates that the level was unchanged from that of the parental 76N primary MECs.
f NA, not applicable, since no viable late-passage cells were detected.
g Immortal MEC indicates the number of experiments in which the presence of immortal colonies was detected out of the total number of experiments performed
(in parentheses).
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forced expression of p14ARF in U2OS cells induces growth
arrest but not senescence (19, 34). As predicted, the transfec-
tion of p14ARF into U2OS cells stabilized p53 and induced
p21cip1 in a dose-dependent manner (Fig. 1B, lanes 1 to 3).
Importantly, cotransfection with E6Y54D abrogated this re-
sponse (lanes 4 to 6). The E6-induced inhibition of p53 stabi-
lization was dose dependent (Fig. 1C, lanes 3 to 6), and
p14ARF-induced p53 stabilization (lanes 1 to 2) was virtually
abolished at the highest input level of E6Y54D (lane 6). We
noticed that, in these experiments, E6Y54D reproducibly in-
creased the levels of the exogenous p14ARF protein (Fig. 1B,
lanes 3 and 6, and C, lanes 2, 5, and 6). p53 was proposed to
inhibit p14ARF expression by an unknown posttranscriptional
mechanism (34), and E6Y54D may release p14ARF from p53
repression.
Like wild-type E6, E6Y54D induces the degradation of
hAda3, which we have implicated in the acetylation and acti-
vation of p53 by p14ARF (31). We therefore reasoned that
E6Y54D would inhibit p53 activation by blocking p53 acetyla-
tion. Since differences in the total p53 levels also could con-
tribute to apparent changes in p53 acetylation, we first nor-
malized U2OS lysates for an input of total p53 and then
detected K382-acetylated p53 in repeated Western blottings
(Fig. 1D). As expected, p14ARF induced the acetylation of
p53. Remarkably, this was completely blocked by E6Y54D, in
agreement with observations for MECs.
FIG. 1. E6Y54D is defective in p53 degradation and inhibits p53 acetylation, stabilization, and growth arrest induced by p14ARF. (A) hTERT
MECs, E6Y54D MECs, and hTERT MECs expressing E6Y54D were infected with pWZL-hygro-p14ARF or control pWZL-hygro retrovirus,
selected with hygromycin, and harvested at day 7 postinfection. Cell lysates corresponding to 30 g protein were analyzed by Western blotting.
Actin was used as a loading control. Note that E6Y54D inhibits p53 stabilization induced by p14ARF. (B) U2OS cells were transfected with
increasing amounts of pcDNA3-p14ARF and 1 g pLXSN-16E6Y54D or vector control. Cells were harvested 48 h posttransfection. p14ARF, p53,
and p21cip1 proteins were detected by Western blotting, and E6 mRNA was detected by RT-PCR. Actin and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were used as loading controls. In U2OS cells, p14ARF induced the dose-dependent stabilization of p53 that was
inhibited by E6Y54D. (C) U2OS cells were transfected with 0.2 g pcDNA3-p14ARF and 0.01, 0.05, 0.2, or 1.0 g pLXSN-16E6Y54D. Cells were
harvested 48 h posttransfection. The expression of p14ARF, total p53, p21cip1, and E6Y54D was detected as described for panel B. E6Y54D inhibited
p14ARF-induced p53 stabilization and the induction of p21cip1. (D) Cell lysates from panel B were normalized for total p53, and the acetylation
of lysine 382 in p53 was detected by Western blotting (lanes 1 and 3, 28 g protein; lane 2, 1.8 g protein; lane 4, 20 g protein). The amount
of HPV16 E6Y54D or empty vector (V) in the transfection was 1 g. (E) U2OS cells were transfected with 0.5 g pEGFPF, 0.2 g
pcDNA3-p14ARF, and 1 g pLXSN-E6Y54D or empty vectors. Monolayer cells were harvested 48 h posttransfection and stained with propidium
iodide, and the DNA content of EGFP-positive cells was analyzed by FACS.
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Since p14ARF induces p53-dependent growth arrest in
U2OS cells (34), we tested the impact of E6Y54D on this re-
sponse. In agreement with the Western blotting data, cell cycle
analysis by a fluorescence-activated cell sorter (FACS) showed
that E6Y54D inhibited p14ARF-induced G1-phase growth ar-
rest (Fig. 1E). Taken together, the results of these experiments
document that in mammary epithelial and U2OS cells, the p53
degradation-defective mutant E6Y54D inhibits p14ARF-in-
duced p53 acetylation, p53 stabilization, p21cip1 induction,
and growth arrest.
E6-induced degradation of Ada3 correlates with efficient
MEC immortalization but is not absolutely required. Based on
the results described above, we considered that HPV16 E6-
mediated hAda3 degradation represents the immortalization
activity of p53 degradation-defective HPV16 E6 mutants. We
attempted to detect levels of endogenous hAda3 protein in the
E6-immortalized MECs by using hAda3 antisera (24, 31); how-
ever, this was unsuccessful, probably due to the very low levels
of endogenous hAda3 protein (data not shown). Therefore, we
used the established cotransfection assay to evaluate the ability
of these HPV E6 mutants to induce p53 and hAda3 degrada-
tion in vivo (15, 18). HPV16 E6 was cotransfected with Flag-
hAda3 or p53 expression plasmids into the p53 null cell line
H1299. E6F2V and E6Y54D reduced Flag-hAda3 protein levels
to extents similar to those of wild-type HPV16 E6 but did not
reduce p53 levels (Fig. 2). These results are in agreement with
those of an earlier study that also used E6F2V and E6Y54H (15).
Therefore, these E6 mutants reduce hAda3 levels, efficiently
immortalize MECs, and maintain normal p53 levels. For com-
parison, we selected mutants E6L37S and E6L110Q, which have
low levels of immortalizing activity (18), and E6L50G and
E6G130V, which did not immortalize MECs (Table 1). These
E6 mutants did not induce p53 or hAda3 degradation in H1299
cells (Fig. 2). Since the expression levels of HPV16 E6 muta-
tions might influence hAda3 degradation, we used RT-PCR to
detect HPV16 E6 mRNA and observed no differences in their
expression levels (lanes 2 to 8). In summary, the E6 mutants
that induce p53 or hAda3 degradation efficiently immortalize
MECs (Table 1). In contrast, E6L37S and E6L110Q, which were
unable to degrade these E6 target proteins, rarely produced
immortal cells.
E6-induced degradation of hAda3 correlates with inhibition
of p14ARF-induced p53 activation and growth arrest. We fur-
ther tested the effects of these E6 mutants on p14ARF-induced
p53 activation and growth arrest in U2OS cells. The levels of
p53 and p21cip1 proteins increased in U2OS cells following
p14ARF transfection (Fig. 3A, lanes 1 and 2). Wild-type
HPV16 decreased the steady-state levels of p53 and abolished
the p14ARF induction of p53 and p21cip1 (lanes 3 and 4).
E6F2V, which is phenotypically similar to E6Y54D in inducing
hAda3 degradation, abrogated p53 stabilization and the induc-
tion of p21cip1 (lanes 5 and 6). In contrast, cells expressing
E6L110Q, E6G130V, and E6L50G, which did not degrade hAda3,
increased p53 levels (lanes 8, 10, and 12). Compared to that of
the control (lane 1), E6G130V and E6L110Q exhibited decreased
basal levels of p21cip, while E6L50G showed no reduction
(lanes 7, 9, and 11). In response to p14ARF, these three mu-
tations showed inductions of p21 levels, with E6L50G-trans-
fected U20S cells exhibiting the greatest increase in p21 pro-
tein levels (Fig. 3A, lanes 11 and 12). Taken together, these
data reveal that the abrogation of p14ARF-induced p53 acti-
vation correlates with the ability of E6 to induce hAda3 deg-
radation.
We then investigated the impact of these E6 mutants on p53
acetylation. Since it was possible that acetylation was not de-
tectable in the cells with low levels of p53, the input protein
was adjusted to normalize total p53 protein levels, and p53
acetylation at lysine 382 was retested (Fig. 3B). The hAda3
degradation-competent mutants E6F2V (Fig. 3B) and E6Y54D
(Fig. 1A) completely blocked p53 acetylation by K382. In con-
trast, E6L110Q, E6G130V, and E6L50G, which do not degrade
hAda3, inhibited p53 acetylation by K382 by about 60%. In-
terestingly, while the percentages of p53 that are acetylated on
K382 in E6L110Q and E6L50G cells were similar, the L110Q
mutant had lower levels of total p53 and, hence, fewer acety-
lated p53 molecules, corresponding to the reduced expression
of p21cip1 (Fig. 3A, compare lanes 7 and 8 to 11 and 12).
Moreover, compared to that of the control, E6L50G did not
inhibit the accumulation of p53 or p21cip1 in response to
p14ARF (Fig. 3A, compare lane 2 to 12).
Using flow cytometry to analyze the cell cycle distribution of
transfected U20S cells, we found that wild-type HPV16 as well
as E6F2V blocked p14ARF-induced growth arrest (G1/S ratios
of 1.1 to 1.5) (Fig. 3C). E6L110Q was less efficient (G1/S ratio of
3.4), while E6G130V- and E6L50G-expressing cells demonstrated
profound G1 arrest, with G1/S ratios of 8.8 and 10.9, respec-
tively. In summary, these experiments demonstrate that hAda3
degradation by HPV16 E6 correlates with the abrogation of
p14ARF-induced p53 acetylation and the inhibition of p53
stabilization and growth arrest.
Low-risk genital HPV6 and HPV11 E6 do not induce hAda3
degradation and do not inhibit p14ARF-p53 signaling. Low-
risk genital HPV6 and HPV11 are associated with benign hy-
perproliferative anogenital and cervical lesions (reviewed in
reference 40). However, in rare cases these types are detected
in malignant lesions, and HPV6vs was isolated from invasive
vulvar carcinoma (27). There are divergent interpretations re-
garding whether low-risk E6 proteins alter p53-dependent re-
FIG. 2. hAda3 and p53 degradation by HPV16 E6 (16E6) mutants
in vivo. H1299 cells were transfected with pcDNA3-Flag-hAda3 (1 g),
pCMV-p53 (1 g), and pLXSN-HPV16 E6 DNA (3 g). Cells were
harvested 48 h posttransfection. The levels of p53 and Flag-hAda3
proteins were analyzed by Western blotting, and E6 mRNA was ana-
lyzed by RT-PCR. Actin and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) were used as loading controls. C, pLXSN vector con-
trol.
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sponses. Low-risk HPV E6 proteins do not induce p53 degra-
dation (6, 12, 29), and HPV6b E6 did not bind hAda3 (15).
However, HPV11 E6 blocked the UV induction of p21cip1
while 16E6L37S did not (35), suggesting that HPV11 E6 inhibits
p53 activation. We tested low-risk E6 for hAda3 degradation
and the inhibition of p14ARF-induced p53 activation. The
expression of HPV6b, HPV6vc, or HPV11 E6 in H1299 cells
did not induce the degradation of Flag-hAda3 and p53 (Fig.
4A). Furthermore, the expression of these E6 types did not
affect p53 stabilization and p21cip1 induction by p14ARF in
U2OS cells (Fig. 4B). In the same experiment, HPV16 E6F2V
blocked the accumulation of p53 and p21cip1. Since the inhi-
bition of p53 stabilization by E6 is dose dependent (Fig. 1C),
we verified the expression of E6 mRNA by RT-PCR. These
data suggest that low-risk HPV E6 proteins do not target
hAda3 and do not inhibit p14ARF signaling to p53.
FIG. 3. Inhibition of p14ARF-induced p53 activation and growth arrest by HPV16 E6 (16E6) mutants that are defective in p53 degradation.
(A) U2OS cells were transfected with 0.2 g p14ARF and 1 g wild-type or mutant HPV16 E6 or empty vector DNA (V). The expression of
p14ARF, p53, and p21cip1 proteins and HPV16 E6 mRNA was detected as described in the legend to Fig. 1B. Asterisks indicate HPV16 E6
mutants defective in both p53 and hAda3 degradation. The graph shows the levels of p53 and p21cip1 quantified using an LAS1000 luminescent
image analyzer (Fuji) and normalized to actin. Levels in control cells transfected with p14ARF (lane 2) were set to 1. Note that E6 and E6F2V
completely blocked the p14ARF-induced accumulation of p53 and p21cip1. (B) Cell lysates from the experiments shown in panel A were
normalized for total p53, and the acetylation of lysine 382 in p53 was detected as described in the legend to Fig. 1D. The graph shows the levels
of acetylated p53 that were quantified and normalized to total p53 as described for panel A. (C) U2OS cells were transfected with GFP-, p14ARF-,
and HPV16 E6-expressing plasmids or control vectors (V). The DNA content of propidium iodide-stained cells was determined by FACS as
described in the legend to Fig. 1E. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Ac-K382-p53, K382-acetylated p53.
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E6-immortalized MECs maintain p14ARF expression. We
reasoned that since E6F2V and E6Y54D induce hAda3 degra-
dation and interfere with p14ARF senescence signals, the re-
spective immortal cells maintain p14ARF expression. For com-
parison purposes, we included MECs immortalized by E6L37S
and E6L110Q, which did not induce hAda3 and p53 degrada-
tion, as well as MECs immortalized by the forced expression of
hTERT. Interestingly, RT-PCR revealed that all MEC lines
immortalized by these E6 mutants maintained the expression
of p14ARF mRNA similarly to the parental 76N cells (Fig. 5A)
irrespective of the ability to degrade hADA3. In contrast,
hTERT MECs dramatically down-regulated p14ARF, in ac-
cordance with our previous report (32). Of note, hTERT
mRNA expression was elevated in all HPV16 E6-immortalized
MECs.
MECs immortalized by hAda3 and p53 degradation-defec-
tive E6 mutants select for proteosomal degradation of the p53
protein. One critical difference between E6L50G and E6G130V,
which are immortalization defective, and E6L37S and E6L110Q,
which are immortalization competent, is that the latter pair
maintains the ability to stimulate the expression of hTERT
(30), although all four are unable to degrade hAda3. The
question remained how these hAda3 and p53 degradation-
defective mutants evade replicative senescence, as they were
unable to abrogate p14ARF signaling to p53. The clue was that
while E6L37S and E6L110Q were unable to acutely induce p53
degradation in MECs, after a latency period in culture, a MEC
population spontaneously arose and proliferated in growth
factor-deficient media for multiple population doublings (18).
As we reported then and confirmed here, compared to those of
parental primary 76N cells, E6L37S- and E6L110Q-immortalized
MECs expressed very low levels of p53 protein, levels that were
comparable to those of wild-type HPV16 E6-immortalized
MECs (Fig. 5B). We also confirmed that the immortal cells
maintain the E6L37S and E6L110Q mutations and express nor-
mal levels of p53 mRNA (data not shown). This fact implies
that cells immortalized by E6L37S and E6L110Q bypass the se-
nescence pathway by secondary events selecting for acceler-
FIG. 4. Low-risk genital HPV E6s do not induce the degradation of
hAda3 and do not inhibit the p14ARF-induced accumulation of p53
and p21cip1. (A) H1299 cells were transfected with Flag-tagged
hAda3, p53, and HPV6b, HPV6vc, HPV11, or HPV16, as described in
the legend to Fig. 2. The expression of Flag-hADA3 and p53 was
tested by Western blotting. Note that, in contrast to HPV16 E6, the
HPV6 and HPV11 E6 do not induce hAda3 degradation. (B) U2OS
cells were transfected with p14ARF, HPV6b E6, HPV6vc E6, HPV16
E6F2V, or empty vector (V), as described in the legend to Fig. 3A. The
expression of p14ARF, p53, and p21cip1 proteins was detected by
Western blotting, and E6 mRNA was detected by RT-PCR. Note that
HPV6 E6 and HPV11 E6 do not inhibit the accumulation of p53 and
p21cip1 proteins induced by p14ARF. HPV16 E6F2V was used for
comparison. Actin was used as a loading control.
FIG. 5. MECs immortalized by hAda3 and p53 degradation-defec-
tive E6 mutants maintain the expression of p14ARF but select for the
proteosomal degradation of the p53 protein. (A) The expression of
p14ARF, hTERT, and HPV16 E6 mRNA was tested by RT-PCR in
parental 76N primary MECs, cells infected with pLXSN vector, or
late-passage HPV16 E6-immortalized MECs (lanes 3 to 7). Glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) was used as the load-
ing control. hTERT-immortalized MECs (lane 8) were used for com-
parison. MCF7 and SAOS2 cell lines were used as PCR standards for
hTERT and p14ARF, respectively. MCF7 is a p14ARF-negative, tel-
omerase-positive breast cancer cell line; SAOS2 is a p14ARF-positive,
telomerase-negative osteosarcoma cell line. Note that the hTERT-
immortalized MECs down-regulate p14ARF compared to the regula-
tion of p14ARF by parental primary 76N MECs. In contrast, 76N
MECs immortalized by wild-type and mutant HPV16 E6 activate
hTERT expression and maintain p14ARF. (B) Cell lysates corre-
sponding to 30 g protein were tested by Western blotting for p53 and
HDM2 proteins. Actin was used as a loading control. In comparison to
E6F2V- or E6Y54D-immortalized MECs, the E6L37S and E6L110Q-im-
mortalized cells exhibit reduced p53 protein levels. Parental primary
76N MECs and wild-type HPV16 E6-immortalized MECs were in-
cluded for comparison. Note that E6L37S- and E6L110Q-immortalized
MECs did not overexpress HDM2. (C) Western blotting of E6L37S-
and E6L110Q-immortalized MECs treated for 4 h with DMSO (lanes 1
and 3) or 10 M proteasome inhibitor MG132 (lanes 2 and 4). Actin
was used as a loading control. 16E6, HPV16 E6.
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ated p53 protein degradation. Multiple factors are known to
regulate p53 turnover, one of which is the ubiquitin ligase
Hdm2, which is overexpressed in a proportion of human tu-
mors, including breast cancers (23). However, Hdm2 protein
levels were not increased in the E6L37S- and E6L110Q-immor-
talized cells (Fig. 5B). Notably, the exposure of these cells to
the proteasome inhibitor MG132 resulted in a robust increase
in p53 protein (Fig. 5C), implying its enhanced turnover in the
immortal cells by the ubiquitin/proteasome pathway.
DISCUSSION
We previously reported that MECs were efficiently immor-
talized by HPV16 E6Y54H and E6F2V, although p53 protein
levels were unchanged compared to those of the parental pri-
mary cells (18). Based on these results, we concluded that
E6-mediated p53 degradation was not strictly necessary for
immortalization. In the same study, E6L37S and E6L110Q were
similarly acutely defective for p53 degradation following the
retroviral infection of MECs and in reticulocyte lysate assays.
However, the few MEC colonies that expressed E6L37S and
E6L110Q that became immortal expressed levels of p53 protein
equal to that of MEC colonies that expressed wild-type E6,
implying selective pressure to abrogate senescence signaling by
p53. Here, we reconcile these seemingly discordant observa-
tions and further elucidate the underlying mechanisms that
allow continuous cell proliferation in culture.
The signaling of p14ARF to p53 is activated in response to
oncogenic stress and results in cell senescence (33). p14ARF-
induced senescence is accompanied by p53 acetylation and
requires the hAda3 protein (31), which complexes with p53
and p300 (15, 37). Previously, we reported that the p53 deg-
radation-defective mutant HPV16 E6Y54D inhibited p14ARF-
induced senescence (32). We now demonstrate that E6 mu-
tants capable of hAda3 degradation but that do not induce p53
degradation also block p14ARF-induced p53 acetylation and
activation in MECs and U20S cells. Taken together with the
fact that dominant-negative hAda3 and hAda3 RNA interfer-
ence inhibit p53 acetylation and p14ARF-p53 signaling (31),
our data strongly imply that the E6 degradation of hAda3 is
sufficient to block p14ARF-induced senescence. The inactiva-
tion of the p14ARF and p53 tumor suppressors is a frequent
event in cancer. The ability of high-risk HPV E6 but not low-
risk HPV E6 to induce hAda3 degradation therefore is likely to
contribute to the oncogenic properties of these viruses.
E6-induced degradation of hAda3 represents one mecha-
nism to inhibit p53 acetylation at lysine 382 and the subsequent
attenuation of p53 function. However, since hAda3 degrada-
tion-defective mutants such as E6L50G also reduced p53 acet-
ylation, albeit less efficiently, other mechanisms may exist. This
notion is supported by observations that HPV16 E6, including
mutants such as E6L50G, bind the HATs CBP/p300 and inhibit
their transcriptional activation activity (25, 39). On this basis,
E6 mutants unable to target Ada3 for degradation also may
interfere with p53 acetylation by HATs. While hAda3 is a
component of multiple HAT complexes, it remains to be de-
termined which HAT is specifically involved in p53 acetylation
in response to p14ARF.
In this study, we found that E6-mediated hAda3 degradation
blocked p14ARF-induced p53 stabilization, which correlated
in part with the inhibition of p53 acetylation by K382. How-
ever, the interplay between p53 acetylation and p53 stabiliza-
tion is complex. E6L50G inhibited p53 acetylation by about
60%, but p53 stabilization induced by p14ARF was not af-
fected. In accord with this observation, the replacement of
several C-terminal lysine residues by arginine, which cannot be
acetylated, had only mild effects on p53 stabilization and func-
tion (9, 14). Interestingly, both E6L110Q and E6L50G reduced
p53 acetylation; however, the former more efficiently inhibited
p53 stabilization and growth arrest following p14ARF expres-
sion than the latter. It appears that p53 acetylation is associ-
ated with but is not equal to p53 activity, since the latter
depends not only on p53 acetylation but also on other p53
modifications (e.g., phosphorylation) and the status of the
other p53-interacting proteins. It is quite likely that, apart from
regulating the activity of HAT(s) toward p53, hAda3 and E6
regulate acetylation and functions of other proteins, such as
protein kinases, that are involved in p53 phosphorylation. In-
terestingly, p14ARF-induced growth arrest is dependent on
the ATM kinase (17) that phosphorylates p53 at serine 15, and
hAda3 is required for serine 15 phosphorylation (24 and V.
Shamanin and E. J. Androphy, unpublished data). Further
mechanistic studies of hAda3 and the role of E6 in p14ARF-
p53 signaling are warranted to explore these intriguing possi-
bilities.
While the role of high-risk E6 in cell transformation is es-
tablished, the functions of E6 proteins from low-risk genital
and cutaneous HPVs remain unknown. Low-risk E6 proteins
do not degrade p53 (6, 29) and have weak immortalizing ac-
tivity in human epithelial cells (2, 11). HPV6 E6 did not bind
hAda3 (15) and did not inhibit DNA damage-induced p53
stabilization and growth arrest (10). In agreement with these
data, we found that HPV6 and HPV11 E6 did not induce
hAda3 degradation and did not alter the p14ARF-induced
accumulation of p53 and p21cip1, implying that low-risk E6
does not affect p53 activation. In contrast, recently it was re-
ported that HPV11 E6 inhibited the p53 activation of the
p21cip1 promoter in vitro and in vivo (35). This disagreement
could be explained by their use of UV light and the stimulation
of the DNA damage response, while our studies used p14ARF.
Interestingly, cutaneous HPV38 E6 does not degrade p53 but
cooperates with E7 in the immortalization of human keratino-
cytes (4, 5). We presently are testing cutaneous E6 proteins for
the ability to inhibit the p14ARF-induced senescence and a
potential role in hAda3 inactivation.
Two mutants previously reported to immortalize MECs with
low efficiency, E6L37S and E6L110Q, were defective for both p53
and hADA3 degradation. Importantly, E6L37S and E6L110Q
retain the full capability to induce hTERT early after expres-
sion in human foreskin keratinocytes (30). Therefore, p53 and
hAda3 degradation is not required for hTERT induction by
E6. Furthermore, inefficient immortalization by hAda3 and
p53 degradation-defective E6 mutants is not due to a defect in
hTERT activation but rather to their inability to block the
p14ARF-p53 pathway. This is supported by the observation
that rare clones of E6L37S and E6L110Q MECs that escaped
senescence have selected for low p53 levels. Interestingly, p53
levels in E6L37S- and E6L110Q-immortalized MECs were re-
stored by MG132, implying the enhanced proteosomal degra-
dation of p53. Our data illustrate three mechanisms of the
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abrogation of the p14ARF-p53 pathway associated with the
immortalization of MECs. First, the serial passage of hTERT-
transduced MECs selects for cells with a reduced expression of
p14ARF mRNA in the presence of wild-type levels of p53 (32).
These cells remain susceptible to p14ARF-induced senes-
cence. Second, cells expressing E6 mutants such as F2V or
Y54D that are capable of degrading hADA3 maintain normal
levels of p53 protein, but p53 activation and acetylation by
p14ARF are blocked. Third, cells with E6 mutant L37S or
L110Q, defective for p53 and hADA3 degradation, avoid rep-
licative senescence by cellular adaptation through the in-
creased turnover of p53 protein. In the latter two conditions,
the immortal cells maintain endogenous p14ARF expression,
because levels of the downstream effector hAda3 or p53 are
reduced (32). Several cellular E3 ligases regulate the proteo-
somal degradation of the p53 protein (13). Hdm2 is the major
E3 ligase involved in p53 regulation, and the overexpression of
Hdm2 was implicated in p53 inactivation in some human can-
cers (23). However, E6L37S- and E6L110Q-immortalized MECs
expressed reduced levels of Hdm2 compared to those of pa-
rental MECs, implying that these cells degrade p53 by activat-
ing another E3 ligase. COP1 and Pirh2 are reasonable candi-
dates, as these are overexpressed in breast and lung cancers (7,
16). Further studies are necessary to identify the p53 ubiquitin
ligase upregulated in E6L37S- and E6L110Q-immortalized
MECs, since this may reveal a molecular marker of the pre-
disposition to and the mechanism of malignant transformation
in breast cancer.
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